Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vericel Corporation (VCEL : NSDQ)

• Company Description    Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. Number of Employees: 357

• Price / Volume Information    Yesterday's Closing Price: $36.43 Daily Weekly Monthly 20 Day Moving Average: 644,103 shares Shares Outstanding: 50.46 (millions) Market Capitalization: $1,838.27 (millions) Beta: 1.39 52 Week High: $63.00 52 Week Low: $29.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.43% 19.33% 12 Week -10.40% -14.90% Year To Date -33.65% -41.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 64 SIDNEY STREET - CAMBRIDGE,MA 02139 USA ph: 617-588-5555 fax: 617-588-5554 ir@vcel.com http://www.vcel.com

• General Corporate Information    Officers Dominick C. Colangelo - President and Chief Executive Officer; Director Robert L. Zerbe - Chairman of the Board of Directors Joseph A. Mara - Chief Financial Officer Jonathan D. Siegal - Vice President and Corporate Controller Alan L. Rubino - Director Peer Information Vericel Corporation (CORR.) Vericel Corporation (RSPI) Vericel Corporation (CGXP) Vericel Corporation (BGEN) Vericel Corporation (GTBP) Vericel Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92346J108 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 50.46 Most Recent Split Date: 10.00 (0.05:1) Beta: 1.39 Market Capitalization: $1,838.27 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.20 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: 185.24 Trailing 12 Months: 303.58 PEG Ratio: - Price Ratios Price/Book: 5.99 Price/Cash Flow: 116.58 Price / Sales: 7.38 EPS Growth vs. Year Ago Period: 90.00% vs. Previous Quarter: 95.65% Sales Growth vs. Year Ago Period: 20.09% vs. Previous Quarter: 20.23% ROE 09/30/25 - - 06/30/25 - 2.47 03/31/25 - 1.09 ROA 09/30/25 - - 06/30/25 - 1.69 03/31/25 - 0.73 Current Ratio 09/30/25 - - 06/30/25 - 4.97 03/31/25 - 5.01 Quick Ratio 09/30/25 - - 06/30/25 - 4.56 03/31/25 - 4.58 Operating Margin 09/30/25 - - 06/30/25 - 2.85 03/31/25 - 1.25 Net Margin 09/30/25 - - 06/30/25 - 2.85 03/31/25 - 1.25 Pre-Tax Margin 09/30/25 - - 06/30/25 - 2.91 03/31/25 - 1.31 Book Value 09/30/25 - - 06/30/25 - 6.08 03/31/25 - 5.89 Inventory Turnover 09/30/25 - - 06/30/25 - 3.94 03/31/25 - 4.02 Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©